𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

✍ Scribed by William Berry; Shaker Dakhil; Mary A Gregurich; Lina Asmar

Book ID
114105352
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
796 KB
Volume
28
Category
Article
ISSN
0093-7754

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Weekly administration of docetaxel for s
Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma : Evaluation of clinical benefit, quality of life, and tolerance
✍ Gwenaelle Gravis; Franck Bladou; Naji Salem; GeneviΓ¨ve Macquart-Moulin; GΓ©rard S πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 94 KB

## Abstract ## BACKGROUND The current Phase II study investigated the clinical benefit, impact on quality of life (QOL), and tolerability of weekly docetaxel in symptomatic patients with metastatic hormone‐refractory prostate carcinoma (HRPC). ## METHODS Patients received weekly docetaxel 35 mg/

Prospective randomized Phase II trial of
Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma
✍ Axel Heidenreich; Frank Sommer; Carsten H. Ohlmann; Andres J. Schrader; Peter Ol πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 120 KB

## Abstract ## BACKGROUND Liposomal encapsulation of doxorubicin has been shown to reduce nonspecific delivery of this agent to normal tissue and to increase specific delivery to malignant cells. On the basis of doxorubicin's demonstrated clinical efficacy against hormone‐refractory prostate carci